Cardiff Oncology, Inc. (CRDF)

Key Insights

• Cardiff Oncology is undergoing a strategic leadership review, with the CEO and CFO stepping down and the Board appointing an experienced interim CEO, Dr. Mani Mohindru, who has a strong background in biotechnology.
• The company announced positive clinical data from its Phase 2 trial of onvansertib in combination with standard-of-care regimens for first-line RAS-mutated metastatic colorectal cancer, suggesting potential for the drug candidate.
• The company has also promoted its Senior Vice President of Finance, Brigitte Lindsay, to the role of Chief Accounting Officer, indicating a focus on strengthening its financial leadership.